What LINE-1 is, where it matters, and why we think it is a tractable therapeutic target
Where current approaches to inhibiting LINE-1 fall short, and what it will take to build the next generation of therapies
Surpassing the 1000 Genomes Project at retrotransposon detection
Using single-cell genomics to reveal how dormant viral-like DNA may shape disease, and to turn those insights into new medicines
An open-source tool for detecting LINE-1 insertions in whole-genome sequencing data
LINE-1 is active in roughly 40% of cancers and is linked to faster progression and treatment resistance - but it is only one factor in a heterogenous disease
Retroviruses evolved from ancient retrotransposons. Some HIV drugs already inhibit LINE-1 - a head start for therapies aimed at diseases of aging
What two very different long-lived species teach us about retrotransposons, evolutionary trade-offs, and disease
